#BEGIN_DRUGCARD DB00919

# AHFS_Codes:
Not Available

# ATC_Codes:
J01XX04

# Absorption:
Rapidly and almost completely absorbed after intramuscular injection.

# Biotransformation:
Not Available

# Brand_Mixtures:
L-S 100 Soluble Powder (Lincomycin (Lincomycin Hydrochloride) + Spectinomycin (Spectinomycin Sulfate))
Lincomycin Spectinomycin 100 Soluble Powder (Lincomycin (Lincomycin Hydrochloride) + Spectinomycin (Spectinomycin Hydrochloride))
Lincomycin Spectinomycin 4.4% G Premix (Lincomycin (Lincomycin Hydrochloride) + Spectinomycin (Spectinomycin Hydrochloride))

# Brand_Names:
Actinospectacin
Spectam
Togamycin
Trobicin

# CAS_Registry_Number:
1695-77-8

# ChEBI_ID:
Not Available

# Chemical_Formula:
C14H24N2O7

# Chemical_IUPAC_Name:
(1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.0^{3,8}]tetradecan-7-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

# Dosage_Forms:
Powder, for suspension	Intramuscular

# Drug_Category:
Aminoglycosides
Anti-Bacterial Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-2.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Easily soluble in cold water

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Spectinomycin

# HET_ID:
SCM

# Half_Life:
1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance &lt; 20 mL per minute.

# InChI_Identifier:
InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1

# InChI_Key:
InChIKey=UNFWWIHTNXNPBV-WXKVUWSESA-N

# Indication:
For use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of <i>Neisseria gonorrhoeae</i>.

# KEGG_Compound_ID:
C02078

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
919

# Mechanism_Of_Action:
Spectinomycin is an inhibitor of protein synthesis in the bacterial cell; the site of action is the 30S ribosomal subunit. It is bactericidal in its action.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
332.3496

# Molecular_Weight_Mono:
332.158351132

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Spectinomycin Pathway	SMP00258

# PharmGKB_ID:
PA164781342

# Pharmacology:
Spectinomycin is an aminocyclitol antibiotic produced by a species of soil microorganism designated as S<i>treptomyces spectabilis</i>. In vitro studies have shown spectinomycin to be active against most strains of <i>Neisseria gonorrhoeae</i> (minimum inhibitory concentration <7.5 to 20 mcg/mL). Footprint studies indicate that spectinomycin exerts regional effects on ribosomal structure.

# Predicted_LogP_Hydrophobicity:
-1.4

# Predicted_LogS:
-0.35

# Predicted_Water_Solubility:
1.50e+02 g/l

# Primary_Accession_No:
DB00919

# Protein_Binding:
Not significant

# PubChem_Compound_ID:
15541

# PubChem_Substance_ID:
46505032

# RxList_Link:
http://www.rxlist.com/cgi/generic/trobicin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01232

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Actinospectacina [Italian]
Antibiotic 2233wp
Espectinomicina [INN-Spanish]
SCM
Spectinomicina [Italian]
Spectinomycin Di HCl
Spectinomycin HCl/ Sulphate
Spectinomycine [INN-French]
Spectinomycinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Acute oral toxicity (LD<sub>50</sub>): >5000 mg/kg [Rat]. Information on overdosage in humans is not available.

# Update_Date:
2013-02-08 16:19:45 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Spectinomycin

# pKa_Isoelectric_Point:
6.95

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11014183	Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6103875	Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9.
6339322	Gordeev VK, Turkov MI: [Functioning of amino acid operons in Escherichia coli strains with an altered transcription and translation apparatus. II. The effect of mutations in genes coding ribosomal protein S5 and translation elongation factor G on the functioning of the ilv operon] Genetika. 1983;19(2):217-20.
6451613	Yamagata H, Dombou M, Sato T, Mizushima S, Uchida H: Deletion mapping and heterogenote analysis of a mutation responsible for osmosis-sensitive growth, spectinomycin resistance, and alteration of cytoplasmic membrane in Escherichia coli. J Bacteriol. 1980 Aug;143(2):661-7.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
V00355

# Drug_Target_1_GenBank_ID_Protein:
43010

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
rpsL

# Drug_Target_1_Gene_Sequence:
>375 bp
ATGGCAACAGTTAACCAGCTGGTACGCAAACCACGTGCTCGCAAAGTTGCGAAAAGCAAC
GTGCCTGCGCTGGAAGCATGCCCGCAAAAACGTGGCGTATGTACTCGTGTATATACTACC
ACTCCTAAAAAACCGAACTCCGCGCTGCGTAAAGTATGCCGTGTTCGTCTGACTAACGGT
TTCGAAGTGACTTCCTACATCGGTGGTGAAGGTCACAACCTGCAGGAGCACTCCGTGATC
CTGATCCGTGGCGGTCGTGTTAAAGACCTCCCGGGTGTTCGTTACCACACCGTACGTGGT
GCGCTTGACTGCTCCGGCGTTAAAGACCGTAAGCAGGCTCGTTCCAAGTATGGCGTGAAG
CGTCCTAAGGCTTAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
10094780	Arnold RJ, Reilly JP: Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal Biochem. 1999 Apr 10;269(1):105-12.
10209746	Toivonen JM, Boocock MR, Jacobs HT: Modelling in Escherichia coli of mutations in mitoribosomal protein S12: novel mutant phenotypes of rpsL. Mol Microbiol. 1999 Mar;31(6):1735-46.
12093756	Valle M, Sengupta J, Swami NK, Grassucci RA, Burkhardt N, Nierhaus KH, Agrawal RK, Frank J: Cryo-EM reveals an active role for aminoacyl-tRNA in the accommodation process. EMBO J. 2002 Jul 1;21(13):3557-67.
12244297	Tung CS, Joseph S, Sanbonmatsu KY: All-atom homology model of the Escherichia coli 30S ribosomal subunit. Nat Struct Biol. 2002 Oct;9(10):750-5.
12379845	Stark H, Rodnina MV, Wieden HJ, Zemlin F, Wintermeyer W, van Heel M: Ribosome interactions of aminoacyl-tRNA and elongation factor Tu in the codon-recognition complex. Nat Struct Biol. 2002 Nov;9(11):849-54.
12809609	Gao H, Sengupta J, Valle M, Korostelev A, Eswar N, Stagg SM, Van Roey P, Agrawal RK, Harvey SC, Sali A, Chapman MS, Frank J: Study of the structural dynamics of the E coli 70S ribosome using real-space refinement. Cell. 2003 Jun 13;113(6):789-801.
151587	Post LE, Arfsten AE, Reusser F, Nomura M: DNA sequences of promoter regions for the str and spc ribosomal protein operons in E. coli. Cell. 1978 Sep;15(1):215-29.
1552908	Timms AR, Steingrimsdottir H, Lehmann AR, Bridges BA: Mutant sequences in the rpsL gene of Escherichia coli B/r: mechanistic implications for spontaneous and ultraviolet light mutagenesis. Mol Gen Genet. 1992 Mar;232(1):89-96.
2477554	Allen PN, Noller HF: Mutations in ribosomal proteins S4 and S12 influence the higher order structure of 16 S ribosomal RNA. J Mol Biol. 1989 Aug 5;208(3):457-68.
320034	Funatsu G, Yaguchi M, Wittmann-Liebold B: Primary stucture of protein S12 from the small Escherichia coli ribosomal subunit. FEBS Lett. 1977 Jan 15;73(1):12-7.
6989816	Post LE, Nomura M: DNA sequences from the str operon of Escherichia coli. J Biol Chem. 1980 May 25;255(10):4660-6.
7556101	Urlaub H, Kruft V, Bischof O, Muller EC, Wittmann-Liebold B: Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995 Sep 15;14(18):4578-88.
8844851	Kowalak JA, Walsh KA: Beta-methylthio-aspartic acid: identification of a novel posttranslational modification in ribosomal protein S12 from Escherichia coli. Protein Sci. 1996 Aug;5(8):1625-32.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
308

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
13606

# Drug_Target_1_Name:
30S ribosomal protein S12

# Drug_Target_1_Number_of_Residues:
123

# Drug_Target_1_PDB_ID:
1P87

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00164	Ribosomal_S12

# Drug_Target_1_Protein_Sequence:
>30S ribosomal protein S12
ATVNQLVRKPRARKVAKSNVPALEACPQKRGVCTRVYTTTPKKPNSALRKVCRVRLTNGF
EVTSYIGGEGHNLQEHSVILIRGGRVKDLPGVRYHTVRGALDCSGVKDRKQARSKYGVKR
PKA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cryo-EM studies suggest that S12 contacts the EF-Tu bound tRNA in the A-site during codon-recognition. This contact is most likely broken as the aminoacyl-tRNA moves into the peptidyl transferase center in the 50S subunit

# Drug_Target_1_SwissProt_ID:
P0A7S3

# Drug_Target_1_SwissProt_Name:
RS12_ECOLI

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
11.49

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00919
